Tarsus Pharmaceuticals (TARS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

TARS Stock Forecast


Tarsus Pharmaceuticals stock forecast is as follows: an average price target of $62.00 (represents a 34.17% upside from TARS’s last price of $46.21) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

TARS Price Target


The average price target for Tarsus Pharmaceuticals (TARS) is $62.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $61.00. This represents a potential 34.17% upside from TARS's last price of $46.21.

TARS Analyst Ratings


Buy

According to 5 Wall Street analysts, Tarsus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for TARS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Tarsus Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Francois BriseboisOppenheimer$63.00$34.5882.17%36.33%
May 13, 2024Oren LivnatH.C. Wainwright$61.00$37.0064.86%32.01%
Row per page
Go to

The latest Tarsus Pharmaceuticals stock forecast, released on Sep 23, 2024 by Francois Brisebois from Oppenheimer, set a price target of $63.00, which represents a 82.17% increase from the stock price at the time of the forecast ($34.58), and a 36.33% increase from TARS last price ($46.21).

Tarsus Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$63.00$62.00
Last Closing Price$46.21$46.21$46.21
Upside/Downside-100.00%36.33%34.17%

In the current month, the average price target of Tarsus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tarsus Pharmaceuticals's last price of $46.21. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2024OppenheimerOutperformOutperformHold
Oct 11, 2024GuggenheimBuyBuyHold
Sep 23, 2024OppenheimerOutperformOutperformHold
May 13, 2024H.C. WainwrightBuyBuyHold
May 10, 2024BarclaysOverweightOverweightHold
May 09, 2024OppenheimerOutperformOutperformHold
Feb 28, 2024OppenheimerOutperformOutperformHold
Jul 25, 2023William BlairOutperformOutperformHold
Row per page
Go to

Tarsus Pharmaceuticals's last stock rating was published by Oppenheimer on Oct 22, 2024. The company gave TARS a "Outperform" rating, the same as its previous rate.

Tarsus Pharmaceuticals Financial Forecast


Tarsus Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue------------$13.08M$1.87M$2.50M$10.00M-$15.28M$539.00K$338.00K$1.24M$22.02M$33.43M
Avg Forecast$174.72M$155.26M$136.45M$125.44M$85.83M$76.32M$67.60M$59.66M$51.43M$43.18M$32.33M$17.89M$5.47M$399.56K$3.33M$10.00M$3.50M$11.25M$5.20M$1.87M$5.33M$4.53M$3.33M
High Forecast$174.72M$155.26M$136.45M$125.44M$85.83M$76.32M$67.60M$59.66M$51.43M$45.30M$32.33M$17.89M$7.11M$399.78K$3.33M$10.00M$3.50M$11.25M$5.20M$1.87M$5.33M$4.53M$3.33M
Low Forecast$174.72M$155.26M$136.45M$125.44M$85.83M$76.32M$67.60M$59.66M$51.43M$40.00M$32.33M$17.89M$2.54M$399.34K$3.33M$10.00M$3.50M$11.25M$5.20M$1.87M$5.33M$4.53M$3.33M
# Analysts44443333454454433334444
Surprise %------------2.39%4.68%0.75%1.00%-1.36%0.10%0.18%0.23%4.86%10.03%

Tarsus Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $17.89M, with a low forecast of $17.89M, and a high forecast of $17.89M. TARS's average Quarter revenue forecast represents a 36.84% increase compared to the company's last Quarter revenue of $13.08M (Dec 23).

Tarsus Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts44443333454454433334444
EBITDA------------$-44.45M$-40.94M$-22.65M$-12.98M$-21.76M$-4.75M$-19.04M$-14.76M$-15.96M$6.50M$10.80M
Avg Forecast$-6.48M$-5.76M$-5.06M$-4.65M$-3.18M$-2.83M$-2.51M$-2.21M$-1.91M$-1.60M$-1.20M$-663.89K$-203.00K$-14.82K$-123.67K$-371.02K$-129.86K$-417.39K$-17.40M$-69.23K$-197.88K$-168.19K$-123.67K
High Forecast$-6.48M$-5.76M$-5.06M$-4.65M$-3.18M$-2.83M$-2.51M$-2.21M$-1.91M$-1.48M$-1.20M$-663.88K$-94.26K$-14.82K$-123.67K$-371.02K$-129.86K$-417.39K$-13.92M$-69.23K$-197.88K$-168.19K$-123.67K
Low Forecast$-6.48M$-5.76M$-5.06M$-4.65M$-3.18M$-2.83M$-2.51M$-2.21M$-1.91M$-1.68M$-1.20M$-663.89K$-263.94K$-14.83K$-123.67K$-371.02K$-129.86K$-417.39K$-20.88M$-69.23K$-197.88K$-168.19K$-123.67K
Surprise %------------218.97%2761.40%183.17%35.00%167.55%11.39%1.09%213.16%80.63%-38.64%-87.30%

4 analysts predict TARS's average Quarter EBITDA for Sep 21 to be $-197.88K, with a high of $-197.88K and a low of $-197.88K. This is -103.04% lower than Tarsus Pharmaceuticals's previous annual EBITDA (Jun 21) of $6.50M.

Tarsus Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts44443333454454433334444
Net Income------------$-41.90M$-39.15M$-21.89M$-13.08M$-22.51M$-6.26M$-20.24M$-14.85M$-15.70M$6.34M$10.38M
Avg Forecast$45.53M$33.04M$23.05M$13.97M$-12.87M$-22.58M$-23.55M$-32.61M$-35.91M$-35.55M$-34.91M$-44.67M$-51.90M$-51.08M$-36.16M$-25.27M$-36.31M$-24.29M$-17.68M$-28.23M$-15.79M$-17.40M$25.53M
High Forecast$45.53M$33.04M$23.05M$13.97M$-12.87M$-22.58M$-23.55M$-32.61M$-35.91M$-32.39M$-34.91M$-44.67M$-44.32M$-51.08M$-36.16M$-25.27M$-36.31M$-24.29M$-14.14M$-28.23M$-15.79M$-17.40M$30.64M
Low Forecast$45.53M$33.04M$23.05M$13.97M$-12.87M$-22.58M$-23.55M$-32.61M$-35.91M$-38.71M$-34.91M$-44.67M$-65.16M$-51.08M$-36.16M$-25.27M$-36.31M$-24.29M$-21.22M$-28.23M$-15.79M$-17.40M$20.43M
Surprise %------------0.81%0.77%0.61%0.52%0.62%0.26%1.14%0.53%0.99%-0.36%0.41%

Tarsus Pharmaceuticals's average Quarter net income forecast for Sep 21 is $-15.79M, with a range of $-15.79M to $-15.79M. TARS's average Quarter net income forecast represents a -348.82% decrease compared to the company's last Quarter net income of $6.34M (Jun 21).

Tarsus Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts44443333454454433334444
SG&A------------$43.01M$30.32M$15.10M$14.63M$11.99M$10.38M$7.95M-$6.67M$6.79M$5.16M
Avg Forecast$364.01M$323.45M$284.27M$261.34M$178.82M$159.01M$140.83M$124.28M$107.14M$89.97M$67.36M$37.28M$11.40M$832.42K$6.94M$20.83M$7.29M$23.44M$10.83M$3.89M$11.11M$9.44M$6.94M
High Forecast$364.01M$323.45M$284.27M$261.34M$178.82M$159.01M$140.83M$124.28M$107.14M$94.38M$67.36M$37.28M$14.82M$832.88K$6.94M$20.83M$7.29M$23.44M$10.83M$3.89M$11.11M$9.44M$6.94M
Low Forecast$364.01M$323.45M$284.27M$261.34M$178.82M$159.01M$140.83M$124.28M$107.14M$83.33M$67.36M$37.28M$5.29M$831.97K$6.94M$20.83M$7.29M$23.44M$10.83M$3.89M$11.11M$9.44M$6.94M
Surprise %------------3.77%36.43%2.17%0.70%1.64%0.44%0.73%-0.60%0.72%0.74%

Tarsus Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $37.28M, based on 4 Wall Street analysts, with a range of $37.28M to $37.28M. The forecast indicates a -13.31% fall compared to TARS last annual SG&A of $43.01M (Dec 23).

Tarsus Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts44443333454454433334444
EPS------------$-0.00$-0.00$-0.82$-0.53$-0.84$-0.26$-0.98$-0.72$-0.76$0.31$0.51
Avg Forecast$1.20$0.87$0.61$0.37$-0.34$-0.60$-0.62$-0.86$-0.95$-0.94$-0.92$-1.18$-1.37$-1.35$-0.96$-0.67$-0.96$-0.64$-0.90$-0.75$-0.42$-0.46$-0.25
High Forecast$1.20$0.87$0.61$0.37$-0.34$-0.60$-0.62$-0.86$-0.95$-0.86$-0.92$-1.18$-1.17$-1.35$-0.96$-0.67$-0.96$-0.64$-0.90$-0.75$-0.42$-0.46$-0.25
Low Forecast$1.20$0.87$0.61$0.37$-0.34$-0.60$-0.62$-0.86$-0.95$-1.02$-0.92$-1.18$-1.72$-1.35$-0.96$-0.67$-0.96$-0.64$-0.90$-0.75$-0.42$-0.46$-0.25
Surprise %------------0.00%0.00%0.86%0.79%0.88%0.40%1.08%0.96%1.82%-0.67%-2.03%

According to 4 Wall Street analysts, Tarsus Pharmaceuticals's projected average Quarter EPS for Sep 21 is $-0.42, with a low estimate of $-0.42 and a high estimate of $-0.42. This represents a -234.65% decrease compared to TARS previous annual EPS of $0.31 (Jun 21).

Tarsus Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HOWLWerewolf Therapeutics$2.26$12.00430.97%Buy
PEPGPepGen$6.79$29.50334.46%Buy
OPTOpthea$4.21$14.00232.54%Buy
NUVBNuvation Bio$2.29$6.75194.76%Buy
ABOSAcumen Pharmaceuticals$2.95$7.00137.29%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
GNFTGenfit$5.76$13.00125.69%Buy
ALDXAldeyra Therapeutics$5.18$11.00112.36%Buy
TYRATyra Biosciences$16.42$30.5085.75%Buy
DSGNDesign Therapeutics$5.32$9.6781.77%Buy
PHVSPharvaris$23.93$39.6765.78%Buy
ETONEton Pharmaceuticals$8.35$13.0055.69%Buy
CNTACentessa Pharmaceuticals$15.89$21.6736.38%Buy
TARSTarsus Pharmaceuticals$46.21$62.0034.17%Buy
CNTBConnect Biopharma$1.20$1.5025.00%Buy
NUVLNuvalent$89.53$107.8320.44%Buy
TVTXTravere Therapeutics$18.10$21.3818.12%Buy
TRDAEntrada Therapeutics$17.77$18.001.29%Buy
IKNAIkena Oncology$1.72$1.33-22.67%Buy

TARS Forecast FAQ


Yes, according to 5 Wall Street analysts, Tarsus Pharmaceuticals (TARS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of TARS's total ratings.

Tarsus Pharmaceuticals (TARS) average price target is $62 with a range of $61 to $63, implying a 34.17% from its last price of $46.21. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for TARS stock, the company can go up by 34.17% (from the last price of $46.21 to the average price target of $62), up by 36.33% based on the highest stock price target, and up by 32.01% based on the lowest stock price target.

TARS's average twelve months analyst stock price target of $62 does not support the claim that Tarsus Pharmaceuticals can reach $70 in the near future.

Tarsus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $289.41M (high $289.41M, low $289.41M), average EBITDA is $-10.738M (high $-10.738M, low $-10.738M), average net income is $-91.612M (high $-91.612M, low $-91.612M), average SG&A $602.94M (high $602.94M, low $602.94M), and average EPS is $-2.422 (high $-2.422, low $-2.422). TARS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $591.87M (high $591.87M, low $591.87M), average EBITDA is $-21.959M (high $-21.959M, low $-21.959M), average net income is $115.58M (high $115.58M, low $115.58M), average SG&A $1.23B (high $1.23B, low $1.23B), and average EPS is $3.06 (high $3.06, low $3.06).

Based on Tarsus Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $17.45M, beating the average analysts forecast of $9.2M by 89.55%. Apple's EBITDA was $-143M, beating the average prediction of $-341K by 41821.21%. The company's net income was $-136M, missing the average estimation of $-139M by -2.33%. Apple's SG&A was $108.7M, beating the average forecast of $19.18M by 466.86%. Lastly, the company's EPS was $-0.0046, missing the average prediction of $-3.679 by -99.87%. In terms of the last quarterly report (Dec 2023), Tarsus Pharmaceuticals's revenue was $13.08M, beating the average analysts' forecast of $5.47M by 138.99%. The company's EBITDA was $-44.45M, beating the average prediction of $-203K by 21796.88%. Tarsus Pharmaceuticals's net income was $-41.902M, missing the average estimation of $-51.897M by -19.26%. The company's SG&A was $43M, beating the average forecast of $11.4M by 277.28%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.372 by -99.91%